HighlightsReceived full production run of approximately 20,000 BPC-157 transdermal patches, the Company's lead product candidatePatches are manufactured and independently tested in the United StatesMarks the Company's transition from testing to commercializationEach patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly trade ...